Beta Bionics (BBNX) analyst forecast and price target
Analyst forecast
Consensus of 14 analyst ratings
Based on 8 analyst targets
Recent analyst ratings
| Firm | Action | Rating | Price target | Date |
|---|---|---|---|---|
| Jefferies | Initiated Coverage | Buy | $30.00 | Oct 12, 2026 |
| Truist Securities | Maintained | Buy | $28.00 from $23.00 | Sep 24, 2026 |
| Wells Fargo | Initiated Coverage | Overweight | $28.00 | Sep 23, 2026 |
| Truist Securities | Maintained | Buy | $23.00 from $22.00 | Sep 15, 2026 |
| B of A Securities | Maintained | Neutral | $20.00 from $18.00 | Sep 15, 2026 |
| Baird | Maintained | Neutral | $16.00 from $14.00 | Sep 15, 2026 |
| Leerink Partners | Maintained | Outperform | $27.00 from $24.00 | Sep 14, 2026 |
| William Blair | Initiated Coverage | Market Perform | — | Aug 21, 2026 |
| UBS | Initiated Coverage | Buy | $22.00 | Jul 28, 2026 |
| Goldman Sachs | Maintained | Buy | $19.00 from $17.00 | Jul 15, 2026 |
| Truist Securities | Maintained | Buy | $22.00 from $18.00 | Jul 13, 2026 |
| Goldman Sachs | Maintained | Buy | $17.00 from $19.00 | May 27, 2026 |
| B of A Securities | Maintained | Neutral | $11.00 from $23.00 | May 18, 2026 |
| Stifel | Maintained | Buy | $20.00 from $22.00 | Apr 22, 2026 |
| Leerink Partners | Maintained | Outperform | $24.00 from $25.00 | Apr 22, 2026 |
| Truist Securities | Maintained | Buy | $18.00 from $25.00 | Apr 15, 2026 |
| Goldman Sachs | Maintained | Buy | $20.00 from $23.00 | Apr 9, 2026 |
| Stifel | Maintained | Buy | $22.00 from $25.00 | Feb 18, 2026 |
| Baird | Maintained | Neutral | $14.00 from $28.00 | Feb 18, 2026 |
| Stifel | Maintained | Buy | $25.00 from $31.00 | Feb 4, 2026 |
Frequently asked questions
What is the price target for BBNX stock?
The average 12-month analyst price target for Beta Bionics (BBNX) is $23.75, with a high estimate of $30.00 and a low of $16.00, across 8 analysts.
Is BBNX a buy, sell, or hold?
Analysts covering Beta Bionics currently average a Buy rating: 10 buy, 4 hold and 0 sell, from 14 analysts. Ratings reflect analyst opinion, not investment advice.
What upside do analysts see for BBNX?
The average price target of $23.75 implies 34.26% upside from the last price of $17.69.
What is the latest analyst rating on BBNX?
On Oct 12, 2026, Jefferies initiated coverage of Beta Bionics at Buy with a price target of $30.00.
Analyst ratings and price targets are the opinions of third-party research firms, not of Light Horse Securities. They are estimates about an uncertain future, are frequently wrong, and are neither a recommendation nor a prediction of actual results.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.